FIELD: pharmaceuticals.
SUBSTANCE: invention relates to new heterocyclic compounds of general formula (I), where A, B, L, X, R1, R2, R3 and R4 are as indicated in the claims, as well as to a method for their preparation and pharmaceutical composition containing the indicated compounds.
EFFECT: compounds have inhibitory activity against monoacylglycerol lipase (MAGL).
34 cl, 2 tbl, 74 ex
Title | Year | Author | Number |
---|---|---|---|
NOVEL HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2019 |
|
RU2769507C1 |
NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | 2019 |
|
RU2801190C2 |
OXAZINMONOACYLGLYCERIN LIPASE (MAGL) INHIBITORS | 2019 |
|
RU2794334C2 |
NEW ISOXAZOLIL ETHER DERIVATIVES AS PAM GABA A ALFA5 | 2019 |
|
RU2800160C2 |
OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | 2014 |
|
RU2674983C1 |
PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | 2020 |
|
RU2811612C2 |
PHARMACEUTICAL PRODUCT CONTAINING INHIBITOR OF SODIUM DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2811864C1 |
BICYCLIC PYRIDINES AND ANALOGUES AS SIRTUIN MODULATORS | 2010 |
|
RU2550821C2 |
CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
Authors
Dates
2023-12-08—Published
2019-11-20—Filed